The monoclonal antibody denosumab demonstrates potent antiresorptive effect in the treatment of osteoporosis, conferring benefit for fracture risk and averting bone loss in select oncological situations. The drug must be used without interruption to prevent a rebound effect, according to Dr Tai-Pang Ip, a consultant endocrinologist from Hong Kong who spoke at AFOS 2017 held in Kuala Lumpur, Malaysia.
Bisphosphonate is one of the first-line therapy for treating osteoporosis, but its long-term use should take into account the balance between its antifracture benefit and risk of adverse events such as atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), according to a presentation at the AFOS 2017 Meeting in Kuala Lumpur, Malaysia.
Patients with type 2 diabetes (T2D) may not necessarily have lower trabecular bone scores (TBS) than nondiabetics, a finding that contrasts with that of previous research, according to a study published in a poster at the recent meeting of the Asian Federation of Osteoporosis Societies (AFOS 2017), held in Kuala Lumpur, Malaysia.
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
The use of functional imaging modalities such as octreotide scintigraphy and 68Ga DOTATATE PET/CT* enhances localization of tumour-induced osteomalacia (TIO), a rare syndrome characterized by bone pain, muscle weakness, and skeletal deformities due to overproduction of the hormone fibroblast growth factor 23 (FGF23), according to data presented at AFOS 2017.
Treatment failure in osteoporosis remains a problem, even among patients who are treatment-adherent, according to a presentation at the recent meeting of the Asian Federation of Osteoporosis Societies (AFOS 2017), held in Kuala Lumpur, Malaysia.
About one in four men in the Philippines had osteoporosis but many were underdiagnosed, with old age (>70 years), history of fracture, and family history of osteoporosis being the main risk factors of developing the condition, according to a study presented at the AFOS 2017 Annual Meeting.
Elderly patients with osteoporotic vertebral fractures (OVF) should refrain from undergoing highly invasive surgery, but those with no posterior wall mobility or paralysis may benefit from balloon kyphoplasty (BKP) for OVF with posterior vertebral wall damage, according to a study presented at the 5th Scientific Meeting Asian Federation of Osteoporosis Societies (AFOS) 2017 in Kuala Lumpur, Malaysia.
Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.